Results 31 to 40 of about 15,808 (143)

Ceftolozane-tazobactam: when, how and why using it?

open access: yes, 2021
Ceftolozane-tazobactam is currently the most active antipseudomonal agent, including multidrug-resistant extensively drug-resistant strains. Tazobactam provides additional activity against many extended-spectrum beta-lactamases Enterobacterales ...
Montero, Maria Milagro   +8 more
core   +1 more source

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

open access: yesTherapeutics and Clinical Risk Management, 2016
Stephanie E Giancola,1 Monica V Mahoney,2 Tiffany E Bias,3,4 Elizabeth B Hirsch2,51Department of Pharmacy, St Mary’s Medical Center, Huntington, WV, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Hahnemann University Hospital, 4Drexel ...
Giancola SE   +3 more
doaj   +1 more source

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa [PDF]

open access: yes, 2017
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed.
Shimose, Luis A   +26 more
core   +2 more sources

Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study

open access: yes, 2021
Objectives: To investigate ceftolozane/tazobactam pharmacokinetics (PK) in plasma and interstitial space fluid (ISF) of muscle and subcutaneous tissue and establish a population PK model.
Dorn, Christoph   +19 more
core   +1 more source

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections

open access: yesAntibiotics, 2022
Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections.
Aisling R. Caffrey   +7 more
doaj   +1 more source

Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2018
Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials.
Golub A.V., Kozlov R.S.
doaj   +1 more source

In vitro activity of ceftolozane/tazobactam against Gram‐negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries—SMART 2017–2019

open access: yesJournal of Global Antimicrobial Resistance, 2022
Objectives: Antimicrobial resistance is one of the top 10 global public-health threats. Especially high rates of resistance have been reported for isolates from ICU patients, requiring expanded treatment options in this setting. We evaluated the activity
Sibylle H. Lob   +7 more
doaj   +1 more source

Comparison of the

open access: yesJournal of Global Antimicrobial Resistance
Objectives: To provide a descriptive analysis of the in vitro antimicrobial susceptibility testing results for all 39,661 Pseudomonas aeruginosa isolates collected by the ATLAS global surveillance programme data from 2020 to 2024 with a focus on ...
Mark A. Estabrook   +3 more
doaj   +1 more source

Association of blaVIM-2, blaPDC-35, blaOXA-10, blaOXA-488 and blaVEB-9 β-Lactamase Genes with Resistance to Ceftazidime–Avibactam and Ceftolozane–Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa

open access: yesAntibiotics, 2022
Ceftazidime–avibactam and ceftolozane–tazobactam are approved for the treatment of complicated Gram-negative bacterial infections including multidrug-resistant (MDR) Pseudomonas aeruginosa.
Mazen A. Sid Ahmed   +10 more
doaj   +1 more source

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]

open access: yes, 2020
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Nicolau, David P   +19 more
core   +1 more source

Home - About - Disclaimer - Privacy